Literature DB >> 2777750

Multiple forms of phospholipase A2 in arthritic synovial fluid.

J J Seilhamer1, S Plant, W Pruzanski, J Schilling, E Stefanski, P Vadas, L K Johnson.   

Abstract

Phospholipase A2 (PLA2) has been purified to homogeneity from human arthritic synovial fluid. The activity resolved into multiple peaks by preparative HPLC. The most abundant peak (A) was present in synovial fluid from patients with rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. A second major peak (B) was variable and lower in relative abundance, but was distinguishable from peak A by its stimulated activity in the presence of either 0.5 M Tris or 0.1% sodium deoxycholate (DOC), in addition to its longer HPLC column retention time. Both peaks required Ca2+ and showed optimal activity in DOC/phosphatidylcholine (PC) mixed micelle assays between pH 8.0 and 9.0. Both peaks showed higher activity with PC as substrate than with PI, however peak A exhibited higher activity with PE than PC. Upon preparative SDS-polyacrylamide gel electrophoresis, both peaks of PLA2 activity were resolved as proteins of approximately 14,000 Da. The N-terminal sequence obtained from purified peak A material matched that of a recent similar isolate (Hara et al. (1988) J. Biochem. 104, 326-328).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777750     DOI: 10.1093/oxfordjournals.jbchem.a122815

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

1.  Purification and inhibitory profile of phospholipase A2 inhibitors from Australian elapid sera.

Authors:  P G Hains; K W Broady
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

2.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; S Tarui; M Okamoto
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  Phospholipase A2 isoforms are altered in chronic pancreatitis.

Authors:  M Kashiwagi; H Friess; W Uhl; H Graber; R Duarte; A Zimmermann; M W Büchler
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

Review 5.  Molecular evolution of toxin genes in Elapidae snakes.

Authors:  Toru Tamiya; Takahiko J Fujimi
Journal:  Mol Divers       Date:  2006-11-10       Impact factor: 2.943

6.  Design of group IIA secreted/synovial phospholipase A(2) inhibitors: an oxadiazolone derivative suppresses chondrocyte prostaglandin E(2) secretion.

Authors:  Jean-Edouard Ombetta; Natacha Thelier; Chang Zhi Dong; Stéphanie Plocki; Lydia Tsagris; François Rannou; France Massicot; Atimé Djimdé; Elissar El-Hayek; Yiming Shi; Françoise Heymans; Nohad Gresh; Caroline Chauvet
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

7.  Phospholipase A2 in human ascitic fluid. Purification, characterization and immunochemical detection.

Authors:  P T Kortesuo; T J Nevalainen
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

8.  Compartmental heterogeneity of soluble phospholipases A.

Authors:  P Vadas; W Pruzanski; E Stefanski; B Sternby
Journal:  Inflammation       Date:  1990-04       Impact factor: 4.092

9.  Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides.

Authors:  C F Bennett; M Y Chiang; L Wilson-Lingardo; J R Wyatt
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

10.  A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.

Authors:  Eric Boilard; Ying Lai; Katherine Larabee; Barbara Balestrieri; Farideh Ghomashchi; Daisuke Fujioka; Reuben Gobezie; Jonathan S Coblyn; Michael E Weinblatt; Elena M Massarotti; Thomas S Thornhill; Maziar Divangahi; Heinz Remold; Gérard Lambeau; Michael H Gelb; Jonathan P Arm; David M Lee
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.